newsfilter
← Latest News
GlobeNewswire·

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals